IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer
{{output}}
Triple-negative breast cancer (TNBC), defined by the absence of ER, PR, and Her2, impacts over 46 000 U.S. women annually, disproportionately affecting minority ethnic groups and individuals with BRCA mutations. Despite advancements such as PARP inhibitors, TN... ...
